Study Section Flaws

The article "NIH Study Section Members Acknowledge Major Flaws in the Reviewing System" (R. Finn, The Scientist, Aug. 21, 1995, page 1) highlights some serious problems that beset a review system that is indeed out of step with the present (financial) times. However, a pattern of funding, apparently prevalent for some time, was not mentioned. Based on National Institutes of Health-published data (Peer Review Trends 1981-1991, DRG Study Section Trends, FY 83-92, Statistics, Analysis and Educati

Written byRobert Cone
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Based on National Institutes of Health-published data (Peer Review Trends 1981-1991, DRG Study Section Trends, FY 83-92, Statistics, Analysis and Education Section, Information Systems Branch, Division of Research Grants, NIH), there is a steady decline in success rates for obtaining a new NIH grant with age. Applicants aged 26-30 are approximately two- to threefold more successful in the award of a new R01 than applicants older than 51.

It has been my experience on (two) NIH study sections that age per se is not cited in reviews. However, the majority of study section members are in an age group younger than 41-45 (DRG Study Section Trends, FY 83-92), and there is a striking parallel between the age composition of the study sections and success rates of age groups. Thus, in contrast to Donna Dean's quote in the article in The Scientist, there is not a "mix of senior and junior ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies